| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Azido-PEG4-NHS ester itself does not bind to a specific biological target. The NHS ester group reacts with primary amines (-NH2) on proteins, antibodies, or other amine-containing molecules to form stable amide bonds. The azide group enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules. As a PROTAC linker, it joins an E3 ubiquitin ligase ligand to a target protein ligand.
|
|---|---|
| ln Vitro |
In vitro activity is primarily related to its function as a bioconjugation or PROTAC linker. It enables the formation of stable conjugates via NHS ester chemistry and click chemistry. PROTACs synthesized using this linker facilitate targeted protein degradation. The PEG spacer provides aqueous solubility. No direct pharmacological activity is attributed to the linker itself.
|
| ln Vivo |
In vivo activity is inferred from the performance of PROTACs or conjugates synthesized using this linker. PROTACs incorporating PEG-based linkers can induce targeted protein degradation in vivo. The PEG spacer improves pharmacokinetic properties by increasing solubility. No direct in vivo activity is associated with the linker alone.
|
| Enzyme Assay |
In vitro assays for Azido-PEG4-NHS ester typically involve evaluating the efficiency of conjugation. The NHS ester is reacted with primary amine-containing molecules at pH 7-9. The azide group is reacted with alkyne-containing molecules via click chemistry. Reaction progress is monitored by HPLC, mass spectrometry, or gel electrophoresis. Purity is assessed by HPLC. Solubility is evaluated in aqueous and organic solvents.
|
| Cell Assay |
Cell-based assays for Azido-PEG4-NHS ester are conducted in the context of the final PROTAC or conjugate molecule. Cells are treated with the conjugate and evaluated for target-specific protein degradation (for PROTACs). Biotinylated or fluorophore-labeled versions of the linker may be used to track cellular uptake and localization via flow cytometry or fluorescence microscopy. Cytotoxicity is measured by MTT or CellTiter-Glo assays.
|
| Animal Protocol |
In vivo animal studies are performed with PROTACs or conjugates containing this linker. Tumor-bearing mice are treated with the conjugate, and tumor growth inhibition is monitored. Pharmacokinetic parameters are evaluated by measuring conjugate levels in blood and tissues. Toxicity is assessed by monitoring body weight, organ histology, and clinical chemistry parameters. The linker's stability in circulation is a key parameter.
|
| ADME/Pharmacokinetics |
Azido-PEG4-NHS ester (molecular weight ~430, formula C17H29N5O8) is a PEG-based linker. The NHS ester is hydrolytically unstable and should be used fresh. The azide group enables click chemistry. No specific PK data are available for this linker alone; its PK profile is determined by the conjugated molecule.
|
| Toxicity/Toxicokinetics |
No detailed toxicology data are specifically available for Azido-PEG4-NHS ester. PEG-based compounds are generally considered to have low toxicity and good biocompatibility. The NHS ester may cause mild irritation. The compound is for research use only and not intended for therapeutic use. Standard laboratory safety precautions should be followed. Store at -20°C.
|
| Additional Infomation |
Azido-PEG4-NHS ester (CAS#: 944251-24-5) is a PEG-based linker containing an azide group and an NHS ester. It is a click chemistry reagent and PROTAC linker. The NHS ester reacts with primary amines, and the azide group enables click chemistry. Molecular weight: ~430, formula: C17H29N5O8.
|
| Molecular Formula |
C15H24N4O8
|
|---|---|
| Molecular Weight |
388.3731
|
| Exact Mass |
388.159
|
| CAS # |
944251-24-5
|
| PubChem CID |
51340931
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
-2.59
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
27
|
| Complexity |
508
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[N-]=[N+]=NCCOCCOCCOCCOCCC(ON1C(=O)CCC1=O)=O
|
| InChi Key |
OIGKWPIMJCPGGD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H24N4O8/c16-18-17-4-6-24-8-10-26-12-11-25-9-7-23-5-3-15(22)27-19-13(20)1-2-14(19)21/h1-12H2
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~257.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 20 mg/mL (51.50 mM) in 10% DMSO + 90% PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
Solubility in Formulation 2: ≥ 2.5 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL corn oil and mix evenly. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5749 mL | 12.8743 mL | 25.7486 mL | |
| 5 mM | 0.5150 mL | 2.5749 mL | 5.1497 mL | |
| 10 mM | 0.2575 mL | 1.2874 mL | 2.5749 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
